Acute skin and hair symptoms followed by severe, delayed eye complications in subjects using the synthetic opioid MT-45
The DOI matches its Crossref record.
Abstract
BACKGROUND: The introduction of unclassified new psychoactive substances (NPS) on the recreational drugs market through open online sale ('legal highs' or 'Internet drugs') continues unabated and represents a growing health hazard. The use of NPS has resulted in numerous, severe, adverse events and fatalities, due to unintended overdose or unknown toxic side-effects. OBJECTIVES: To try to find a possible common underlying cause for the skin-hair-eye symptoms complex observed in three men. METHODS: From late 2013 to mid-2014, three Swedish men aged 23-34 years with a history of recreational drug use independently presented with similar and very remarkable clinical signs, requiring extensive examination and prolonged treatment. RESULTS: Common clinical signs included hair depigmentation, hair loss, widespread folliculitis and dermatitis, painful intertriginous dermatitis, dry eyes, and elevated liver enzymes. Two of them also showed transverse white Mees' lines (leukonychia striata) on the fingernails and toenails, suggesting a temporary, drug-induced, disorganized keratinization. The clinical signs gradually disappeared over time. However, later on, two developed severe bilateral secondary cataracts requiring surgery. Because drug tests within the Swedish STRIDA project had demonstrated intake of the NPS opioid MT-45 in all patients, this was suspected to be the common causative agent. CONCLUSIONS: These cases highlight the importance for physicians and health professionals to consider the increasing number of novel, untested recreational drugs, as a potential cause of unusual and otherwise unrecognized clinical signs and symptoms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Fentanyl, fentanyl analogs and novel synthetic opioids: A comprehensive review
Armenian, P., Vo, K. T., Barr-Walker, J., & Lynch, K. L. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.10.016 · Cited by 710
Designer drugs: mechanism of action and adverse effects
Luethi, D., & Liechti, M. E. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02693-7 · Cited by 262
Baumann, M. H., Majumdar, S., Le Rouzic, V., Hunkele, A., Uprety, R., Huang, X. P., Xu, J., Roth, B. L., Pan, Y.-X., & Pasternak, G. W. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.08.016 · Cited by 92
“It is tempting to speculate that the unique in vitro pharmacology of MT-45 might underlie its unusual clinical side-effects which include a deep level of unconsciousness, ototoxicity, hair loss and dermatitis (Helander et al., 2014; Helander et al., 2017).”
BackgroundBilel, S., Azevedo Neto, J., Arfè, R., Tirri, M., Gaudio, R. M., Fantinati, A., Bernardi, T., Boccuto, F., Marchetti, B., Corli, G., et al. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109020 · Cited by 34
“…et al. Neuropharmacology 209 (2022) 109020 FENT via intracellular mechanisms that involves β-arrestins signaling (Bohn et al., 2004; Raehal& Bohn, 2011) and thus increasing their risk of abuse toxicity and death with overdose (Helander et al., 2017; Kuczyńska et al., 2018; Frisoni et al., 2018).”
BackgroundIn vitro and in vivo pharmacological characterization of the synthetic opioid MT-45
Bilel, S., Azevedo, N., Arfè, R., Tirri, M., Gregori, A., Serpelloni, G., De-Giorgio, F., Frisoni, P., Neri, M., Calò, G., et al. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108110 · Cited by 32
Metadata
- Authors
- Helander, A., Bradley, M., Hasselblad, A., Norlén, L., Vassilaki, I., Bäckberg, M., & Lapins, J.
- Venue
- British Journal of Dermatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-12-14
- Volume
- 176
- Issue
- 4
- Pages
- 1021-1027
- ISSN
- 0007-0963 (ISSN-L)
- OpenAlex
- W2564575017
- Cited by
- 78
- References
- 0
- FWCI
- 9.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.